MARKET

ARTL

ARTL

Artelo Biosciences Inc
NASDAQ
1.499
+0.039
+2.70%
Opening 10:08 05/29 EDT
OPEN
1.450
PREV CLOSE
1.460
HIGH
1.500
LOW
1.410
VOLUME
167.61K
TURNOVER
--
52 WEEK HIGH
85.80
52 WEEK LOW
1.190
MARKET CAP
5.23M
P/E (TTM)
-0.0385
1D
5D
1M
3M
1Y
5Y
1D
Artelo Biosciences Launches Flexible At-The-Market Offering
TipRanks · 1d ago
Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results
Benzinga · 1d ago
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results
Benzinga · 2d ago
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 2d ago
Artelo Biosciences announces annual shareholder meeting
PUBT · 2d ago
Artelo Biosciences Files Prospectus To Offer Up To $6.53M In Common Stock Via H.C. Wainwright
Benzinga · 2d ago
ARTELO BIOSCIENCES INC - TO OFFER UP TO $6.53 MLN IN COMMON STOCK VIA H.C. WAINWRIGHT - SEC FILING
Reuters · 2d ago
More
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Webull offers Artelo Biosciences Inc stock information, including NASDAQ: ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.